Pradyumna Agasthi
Cardiovascular Disease · Muskogee, OKNPI 1184034134
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.7%), travel and lodging and grants — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.6%. 2025 is the largest year on record at $2,606, 2.2 times the $1,192 reported in 2019.
Across 114 payments — averaging $77.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- Edwards Lifesciences$2K
- Abbott$748
- Cook Medical LLC$676
- Abiomed$549
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$541%
- Grants$6768%
- Travel & lodging$3,83844%
- Food & beverage$4,10347%
- Education$1181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $1,983 |
| Medtronic(2 entities) | 36 | $1,811 |
| Edwards Lifesciences | 18 | $1,756 |
| Abbott | 12 | $748 |
| Cook Medical LLC | 1 | $676 |
| Abiomed | 7 | $549 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $263 |
| Angiodynamics, Inc. | 3 | $235 |
| Penumbra, Inc. | 1 | $150 |
| Johnson & Johnson | 1 | $123 |
| Cardinal Health 200 LLC | 2 | $92 |
| Heartflow, Inc. | 1 | $54 |
| Pfizer | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Merck | 3 | $47 |
| Stryker | 1 | $34 |
| Amgen | 2 | $34 |
| Novartis | 1 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $28 |
| BD | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,788 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 147 | $131,642 |
| JardianceEmpagliflozin | 153 | $123,701 |
| Praluent PenAlirocumab | 38 | $22,378 |
| XareltoRivaroxaban | 17 | $19,356 |
| Repatha SureclickEvolocumab | 30 | $17,706 |
| FarxigaDapagliflozin Propanediol | 18 | $16,159 |
| EntrestoSacubitril/Valsartan | 12 | $8,011 |
| Metoprolol Succinate | 200 | $4,224 |
| Rosuvastatin Calcium | 227 | $3,323 |
| Carvedilol | 121 | $1,597 |
| Losartan Potassium | 107 | $1,295 |
| Spironolactone | 87 | $945 |
| Digoxin | 21 | $801 |
| Atorvastatin Calcium | 82 | $690 |
| ClopidogrelClopidogrel Bisulfate | 42 | $682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $131,642147 claims |
| Boehringer IngelheimJardiance | $16 | $123,701153 claims |
| Johnson & JohnsonXarelto | $123 | $19,35617 claims |
| NovartisEntresto | $30 | $8,01112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Muskogee
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
- Reji PappyOklahoma City$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.